Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall response rate
Lev Demidov, MD, D.Sc.
N.N. Blokhin Russian Cancer Research Center
Russia: Ministry of Health of the Russian Federation